Literature DB >> 11213096

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

L Kyne1, M Warny, A Qamar, C P Kelly.   

Abstract

BACKGROUND: We have reported that symptom-free carriers of Clostridium difficile have a systemic anamnestic immune response to toxin A. The aim of this study was to determine whether an acquired immune response to toxin A, during an episode of C. difficile diarrhoea, influences risk of recurrence.
METHODS: We prospectively studied 63 patients with nosocomial C. difficile diarrhoea. Serial serum IgA, IgG, and IgM concentrations against C. difficile toxin A, toxin B, or non-toxin antigens were measured by ELISA. Individuals were followed for 60 days.
FINDINGS: 19 patients died (30%). Of the 44 who survived, 22 had recurrent C. difficile diarrhoea. Patients with a single episode of C. difficile diarrhoea (n=22) had higher concentrations of serum IgM against toxin A on day 3 of their first episode of diarrhoea than those with recurrent diarrhoea (n=22, p=0.004). On day 12, serum IgG values against toxin A were higher in patients who had a single episode of diarrhoea (n=7) than in those who subsequently had recurrent diarrhoea (n=9, p=0.009). The odds ratio for recurrence associated with a low concentration of serum IgG against toxin A, measured 12 days after onset of C. difficile diarrhoea, was 48.0 (95% CI 3.5-663).
INTERPRETATION: A serum antibody response to toxin A, during an initial episode of C. difficile diarrhoea, is associated with protection against recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11213096     DOI: 10.1016/S0140-6736(00)03592-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  238 in total

Review 1.  Recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; C P Kelly
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

3.  Prevention of healthcare‐associated Clostridium difficile infection: what works?

Authors:  Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

Review 4.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

5.  Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea.

Authors:  I L P Beales
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

6.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

Review 7.  Acute and chronic pouchitis--pathogenesis, diagnosis and treatment.

Authors:  Bo Shen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-04-17       Impact factor: 46.802

Review 8.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

9.  Medical microbiology: A toxin contest.

Authors:  Jimmy D Ballard
Journal:  Nature       Date:  2010-10-07       Impact factor: 49.962

10.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.